Get the Stockscreener App
1.93
4.32%
0.08
Metagenomi Inc stock is traded at $1.93, with a volume of 236.55K.
It is up +4.32% in the last 24 hours and down -17.17% over the past month.
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.
See More
Previous Close:
$1.85
Open:
$1.86
24h Volume:
236.55K
Relative Volume:
0.39
Market Cap:
$72.44M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+3.76%
1M Performance:
-17.17%
6M Performance:
-18.22%
1Y Performance:
-36.93%
1-Day Range:
$1.86
$2.00
1-Week Range:
$1.77
$2.00
52-Week Range:
$1.23
$4.92
Metagenomi Inc Stock (MGX) Company Profile
Name
Metagenomi Inc
Sector
Industry
Phone
(510) 871-4880
Address
5959 HORTON STREET, EMERYVILLE
Compare MGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MGX
Metagenomi Inc
|
1.93 | 72.06M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Metagenomi Inc Stock (MGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-07-24 | Initiated | H.C. Wainwright | Buy |
| May-02-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-05-24 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-24 | Initiated | Chardan Capital Markets | Buy |
| Mar-05-24 | Initiated | JP Morgan | Overweight |
| Mar-05-24 | Initiated | Jefferies | Buy |
| Mar-05-24 | Initiated | TD Cowen | Outperform |
| Mar-05-24 | Initiated | Wells Fargo | Overweight |
View All
Metagenomi Inc Stock (MGX) Latest News
North American Morning Briefing : Stock Futures -2- - MarketScreener
Metagenomi shares rise 2.15% intraday after Chardan cuts price target to $11. - AInvest
Chardan Cuts Price Target on Metagenomi to $11 From $12, Keeps Buy Rating - MarketScreener
Is Metagenomi Inc. stock entering bullish territoryWeekly Market Report & Technical Pattern Based Signals - Newser
What machine learning models say about Metagenomi Inc.Earnings Overview Report & Low Drawdown Trading Techniques - Newser
Will Metagenomi Inc. stock benefit from AI tech trendsWeekly Investment Recap & Community Supported Trade Ideas - Newser
What does recent volatility data suggest for Metagenomi Inc.Portfolio Risk Report & Weekly High Conviction Trade Ideas - Newser
Metagenomi Reports Strong Q2 2025 Financial Results - MSN
Metagenomi Inc. stock trendline breakdownBuy Signal & Weekly Stock Performance Updates - Newser
Wells Fargo & Company Cuts Metagenomi (NASDAQ:MGX) Price Target to $12.00 - Defense World
Chardan Capital Lowers Metagenomi (NASDAQ:MGX) Price Target to $11.00 - Defense World
Metagenomi price target lowered to $11 from $12 at Chardan - MSN
Smart tools for monitoring Metagenomi Inc.’s price action2025 Volume Leaders & Expert Curated Trade Ideas - Newser
How Metagenomi Inc. stock performs during market volatilityJuly 2025 Decliners & Free Expert Approved Momentum Trade Ideas - 선데이타임즈
Will Metagenomi Inc. outperform tech stocksDollar Strength & Community Verified Trade Alerts - mustnews.co.kr
Price Floor Holding on Metagenomi Inc. — Rebound Possible2025 Trade Ideas & Detailed Earnings Play Alerts - beatles.ru
Analyst Downgrades and Divergent Price Targets for Metagenomi (MGX): Is the Pessimism Justified? - AInvest
Metagenomi Earnings: Analysts Trim Price Target Amid Revenue Beat and Loss Increase - AInvest
Analysts Have Been Trimming Their Metagenomi, Inc. (NASDAQ:MGX) Price Target After Its Latest Report - Yahoo Finance
Metagenomi Inc. Sees Spike in Bullish Option FlowMarket Volume Report & Weekly Top Gainers Alerts - beatles.ru
Jasper Therapeutics shares rise 3.51% intraday after Metagenomi reported positive business updates and financial results. - AInvest
Regeneron Pharmaceuticals shares rise 1.12% intraday after Metagenomi reported positive business updates and financial results. - AInvest
Metagenomi: Q2 Earnings Snapshot - Greenwich Time
Metagenomi (MGX) Reports Q2 Loss, Tops Revenue Estimates - MSN
Crispr Therapeutics shares rise 1.10% premarket after Metagenomi reported positive business updates and financial results. - AInvest
Metagenomi Reports Business Updates and Second Quarter 2025 Financial Results - GlobeNewswire
Metagenomi 2025 Q2 Earnings Sharp Widening of Losses - AInvest
Metagenomi's Q2 Earnings: A Biotech Underdog's Path to Validation - AInvest
Metagenomi, Inc. SEC 10-Q Report - TradingView
Press Release: Metagenomi Reports Business Updates and Second Quarter 2025 Financial Results - 富途牛牛
Metagenomics Market Size, Share, Growth, Trends | Industry Report 2033 - Straits Research
Jasper Therapeutics shares rise 5.70% intraday after Metagenomi appoints Laurence Reid, PhD to its Board of Directors. - AInvest
Metagenomi shares rise 1.09% premarket after appointing Laurence Reid, PhD to its Board of Directors. - AInvest
Metagenomi (MGX) to Release Quarterly Earnings on Wednesday - Defense World
Metagenomi Appoints Laurence Reid, PhD to its Board of Directors - GlobeNewswire
Metagenomi appoints biotech veteran Laurence Reid to board of directors By Investing.com - Investing.com Canada
Metagenomi appoints biotech veteran Laurence Reid to board of directors - Investing.com India
Metagenomi Appoints Laurence Reid to Board of Directors - AInvest
Gene Editing Pioneer Metagenomi Taps Former Decibel CEO Laurence Reid to Accelerate Clinical Pipeline - Stock Titan
Will Metagenomi Inc. benefit from macro trendsAI-Based Reversal Point Prediction Signal - Newser
Historical volatility pattern of Metagenomi Inc. visualizedControlled Entry Strategy With Safety Analytics - Newser
Metagenomi MGX 2025Q2 Earnings Preview Upside Potential Driven by Strategic Partnerships - AInvest
Price momentum metrics for Metagenomi Inc. explainedReal-Time Investment Signal Forecast with AI - Newser
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 25, 2024 in Metagenomi LawsuitMGX - ACCESS Newswire
Metagenomi, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before November 25, 2024 to Discuss Your RightsMGX - ACCESS Newswire
Metagenomi, Inc. (NASDAQ:MGX) Shares Purchased by Bank of New York Mellon Corp - Defense World
Metagenomi Sells The Gene-Editing Dream—But Risk Looms Large - Finimize
How does Metagenomi Inc. compare to its industry peersTremendous return rates - Jammu Links News
When is Metagenomi Inc. stock expected to show significant growthBreakneck growth rates - Jammu Links News
Published on: 2025-08-04 03:23:40 - Jammu Links News
Metagenomi Inc Stock (MGX) Financials Data
There is no financial data for Metagenomi Inc (MGX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Metagenomi Inc Stock (MGX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Wein Matthew | See Remarks |
Jun 06 '25 |
Sale |
1.75 |
199 |
348 |
16,693 |
| Noonberg Sarah B. | Chief Medical Officer |
Jun 06 '25 |
Sale |
1.75 |
5,239 |
9,168 |
109,135 |
| Wapnick Pamela | Chief Financial Officer |
Jun 06 '25 |
Sale |
1.75 |
1,576 |
2,758 |
72,108 |
| Thomas Brian C. | Chief Executive Officer |
Jun 06 '25 |
Sale |
1.75 |
10,785 |
18,874 |
2,517,491 |
| Irish Jian | See Remarks |
Jun 06 '25 |
Sale |
1.75 |
6,390 |
11,182 |
315,543 |
| Wein Matthew | See Remarks |
Mar 05 '25 |
Sale |
1.87 |
930 |
1,744 |
9,467 |
| Wapnick Pamela | Chief Financial Officer |
Mar 05 '25 |
Sale |
1.87 |
1,808 |
3,390 |
59,684 |
| Wapnick Pamela | Chief Financial Officer |
Dec 05 '24 |
Sale |
1.86 |
1,559 |
2,900 |
61,492 |
| Wapnick Pamela | Chief Financial Officer |
Sep 05 '24 |
Sale |
2.88 |
6,265 |
18,043 |
63,051 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):